Developer docs
API playgroundTry for free, no card

Search company profiles

Bioscope AI

Full company profile

uuid003ycp8

Namestring
Bioscope AI
Legal namestring
Bioscope.ai, Inc.
Websiteurl
bioscope.ai
Company typeenum
Private
Founded yearint
2025
Descriptiontext

Bioscope AI is a privately held US company (incorporated in Indiana, headquartered in Carmel) that sells a cloud-based clinical decision-support platform for licensed physicians and medical practices. The platform synthesizes whole-genome sequencing (30x coverage, ~3.2 billion base pairs, 20,000-25,000 genes), microbiome analysis, electronic medical record data, and laboratory results into a single per-patient longitudinal view, then surfaces AI-generated clinical insights, polygenic risk scores, pharmacogenomic flags (22 PGx variants), and dimension-by-dimension findings (renal, cardiovascular, metabolic, neurocognitive, longevity, cancer, immune, gut, hepatic, blood) through an AI chat interface. The company's core technological differentiator is an evidence-grounded reasoning layer with controlled chains designed to prevent hallucination, delivered on HIPAA-compliant infrastructure with AES-256 encryption, TLS 1.3, MFA, and BAA-ready contracting.

The company operates a hybrid go-to-market: an enterprise field-sales motion offering 30-minute demos covering EMR integration, patient enrollment, and a sample case, paired with a self-service 'Try It On Yourself' product-led growth funnel for individual physicians. Revenue is generated through SaaS subscriptions to the cloud platform (annual, auto-renewing) and laboratory testing services for whole-genome sequencing and microbiome analysis performed by contracted testing labs. The primary customer segment is horizontal: concierge physicians, primary care doctors, and medical practices seeking to deliver precision medicine with limited time per visit. The only publicly named customer is Austin Concierge Medicine; the operating footprint is US-only. The leadership team is in buildout mode, with a CTO (Felix Wyss) appointed March 2026 and a CMO (Dr. Helen Messier) appointed February 2026, and a 'Try It On Yourself' program launched in October 2025. No funding rounds, revenue figures, or customer counts are disclosed.

Short descriptiontext

Bioscope AI is a private US health-tech company that sells a HIPAA-compliant cloud platform combining whole-genome sequencing, microbiome analysis, and EMR data with AI-powered clinical decision support, targeted at concierge physicians and medical practices seeking to deliver precision medicine during patient visits.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersCarmel, United States
HQ citystring
Carmel
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
genomic clinical decision support, whole-genome sequencing, precision medicine platform, AI clinical analytics, microbiome analysis services
Industry3 codes
PRIMARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)
SECONDARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories
NAICS code2 codes
  • Medical and Diagnostic Laboratories6215
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Medical Laboratories8071
Product category
Clinical Decision Support Software
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1SaaS Subscription for Healthcare Practices
TypeSubscription Recurring
Description

Subscription-based access to the Bioscope.ai cloud-based software platform for medical groups and practices. Physicians pay subscription fees to access AI-powered genomic analysis and clinical decision support tools integrated with their patient workflow.

bioscope.ai
2Laboratory Testing Services
TypeProfessional Services
Description

Whole genome sequencing and microbiome analysis services ordered by healthcare providers on behalf of patients. The testing includes sample collection kits and processing through contracted testing laboratories.

Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations
Pricing details1 tier
1Subscription-based SaaS platform access for medical practices
ModelSubscriptionBilling cadenceAnnual
Notes

Subscription fees are listed in the Order. Subscriptions auto-renew for additional periods equal to the expiring term unless either party gives 60 days notice of non-renewal.

GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Bioscope AI sells a cloud-based, HIPAA-compliant clinical decision support SaaS platform that synthesizes whole-genome sequencing (~30x coverage), microbiome analysis, electronic medical records, and lab results into physician-ready clinical insights. Licensed clinicians access an AI chat interface with controlled reasoning chains that flags 22 pharmacogenomic variants and surfaces findings across 15 health dimensions (Metabolic, Cardiovascular, Neurocognitive, Longevity, Immune, Gut, Renal, Hepatic, Cancer, etc.). The company also offers laboratory testing services (whole-genome sequencing and microbiome analysis) and a "Try It On Yourself" self-signup program for individual physician self-analysis.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Most physicians are operational within a week of EMR integration
+1 more record
Product overview1 text field

Bioscope.ai is a clinical AI platform built as a unified SaaS offering combining genetic analysis with AI-powered clinical decision support. The core Bioscope.ai Platform serves as the central hub, supported by whole-genome sequencing and microbiome analysis laboratory services. Key modules include an AI Chat Interface for natural language queries, pharmacogenomics (PGx) analysis, and EHR Integration Services. The Try It On Yourself Program enables physicians to personally experience the platform by analyzing their own health data. The platform is accessed via the HIPAA-compliant app.us.bioscope.ai web application.

Product and service4 records
1Bioscope.ai Platform
CategoryClinical decision support / precision medicine SaaS
Description

HIPAA-compliant, cloud-based clinical decision support platform for physicians and medical practices that reads whole-genome sequencing, microbiome, lab, and full patient history data and synthesizes them into clinical insights before patient visits. Includes the AI Chat Interface, pharmacogenomic analysis, and EMR integration.

2Whole-Genome Sequencing
CategoryLaboratory testing services
Description

Laboratory testing service that sequences patient samples at ~30x average coverage, reading approximately 3.2 billion base pairs across 20,000–25,000 genes with all variants reviewed against the latest clinical databases. Ordered by healthcare providers on behalf of patients, with at-home or in-office collection kits.

3Microbiome Analysis
CategoryLaboratory testing services
Description

Laboratory testing service that analyzes DNA of microorganisms from stool samples to provide clinical insights into microbial composition and function, ordered by healthcare providers for patients as an optional add-on to whole-genome sequencing.

4Try It On Yourself Program
CategorySelf-service physician program
Description

Self-service offering for individual physicians to use Bioscope AI's clinical AI and genomics capabilities on themselves, including self-enrollment, personal medical data upload, and ordering of whole-genome and microbiome testing kits, intended as a validation path before practice-wide recommendation.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeOthers
Description

Bioscope AI contracts with qualified laboratories to perform whole genome sequencing and microbiome analysis on patient samples. A current list of Testing Laboratories is maintained on the Subprocessors page. These laboratories hold appropriate certifications and accreditations for genetic testing services.

Strategic tierCoreTypeTechnology or Integration
Description

Auth0 provides secure authentication and session management for the HIPAA-compliant healthcare platform (app.us.bioscope.ai). Uses encrypted session identifiers with HttpOnly and Secure flags, device identifiers for security monitoring, and automatic session termination after 15 minutes of inactivity.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Foundation Medicine provides molecular profiling and genomic analysis to oncologists at scale within the Roche ecosystem; a broad incumbent in clinical genomics whose CDSS-adjacent services compete for the same physician mindshare bioscope.ai targets.

TypeDirect peer
Description

SOPHiA Genetics operates an AI-driven genomics interpretation platform used by hospitals and clinicians worldwide for clinical decision support, closely paralleling bioscope.ai's evidence-grounded AI for genomic/multi-omic clinical insights.

3Tempus Labs
TypeDirect peer
Description

Tempus AI combines multi-modal data (genomics, transcriptomics, imaging, clinical records) with AI to deliver clinical decision support and precision medicine insights to physicians — directly comparable to bioscope.ai's WGS + EMR + AI CDSS model across target customer profile.

TypeDirect peer
Description

Helix operates a whole-exome / whole-genome sequencing platform powering clinical and population genomics applications — closely aligned with bioscope.ai's 30x WGS foundation and clinical decision support build.

TypeEmerging player
Description

Owkin applies AI to multi-modal clinical and omics data for treatment decision support and drug discovery, overlapping with bioscope.ai's clinician-facing AI analytics on genomic and clinical data.

TypeEmerging player
Description

Genomind provides PGx and mental-health genetic testing for clinicians — a smaller, niche player in genetic clinical decision support that overlaps with bioscope.ai's PGx module and physician-facing workflow.

TypeBroad incumbent
Description

GeneDx delivers clinical genomic sequencing and interpretation (rare disease, hereditary cancer, PGx) at scale — a broader incumbent whose CDSS-adjacent workflow overlaps with bioscope.ai's clinical genomics offering.

TypeBroad incumbent
Description

Caris provides molecular profiling (WGS, WTS, proteomics) and AI-driven insights for oncologists, comparable to bioscope.ai's whole-genome + AI clinical decision support model within oncology-focused precision medicine.

TypeDirect peer
Description

Color combines clinical-grade genetic testing with a clinician-facing platform spanning hereditary cancer, pharmacogenomics, and population health — directly comparable to bioscope.ai's WGS + PGx + clinical workflow offering.

TypeBroad incumbent
Description

Verily is a health-data and precision-medicine platform within Alphabet pursuing AI-driven clinical research and care delivery; broadly comparable to bioscope.ai's data-aggregation approach to clinical AI.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance6 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Bioscope AI

Clinical Decision Support Softwarebioscope.ai

Bioscope AI is a private US health-tech company that sells a HIPAA-compliant cloud platform combining whole-genome sequencing, microbiome analysis, and EMR data with AI-powered clinical decision support, targeted at concierge physicians and medical practices seeking to deliver precision medicine during patient visits.

What Bioscope AI does

Bioscope AI is a privately held US company (incorporated in Indiana, headquartered in Carmel) that sells a cloud-based clinical decision-support platform for licensed physicians and medical practices. The platform synthesizes whole-genome sequencing (30x coverage, ~3.2 billion base pairs, 20,000-25,000 genes), microbiome analysis, electronic medical record data, and laboratory results into a single per-patient longitudinal view, then surfaces AI-generated clinical insights, polygenic risk scores, pharmacogenomic flags (22 PGx variants), and dimension-by-dimension findings (renal, cardiovascular, metabolic, neurocognitive, longevity, cancer, immune, gut, hepatic, blood) through an AI chat interface. The company's core technological differentiator is an evidence-grounded reasoning layer with controlled chains designed to prevent hallucination, delivered on HIPAA-compliant infrastructure with AES-256 encryption, TLS 1.3, MFA, and BAA-ready contracting.

The company operates a hybrid go-to-market: an enterprise field-sales motion offering 30-minute demos covering EMR integration, patient enrollment, and a sample case, paired with a self-service 'Try It On Yourself' product-led growth funnel for individual physicians. Revenue is generated through SaaS subscriptions to the cloud platform (annual, auto-renewing) and laboratory testing services for whole-genome sequencing and microbiome analysis performed by contracted testing labs. The primary customer segment is horizontal: concierge physicians, primary care doctors, and medical practices seeking to deliver precision medicine with limited time per visit. The only publicly named customer is Austin Concierge Medicine; the operating footprint is US-only. The leadership team is in buildout mode, with a CTO (Felix Wyss) appointed March 2026 and a CMO (Dr. Helen Messier) appointed February 2026, and a 'Try It On Yourself' program launched in October 2025. No funding rounds, revenue figures, or customer counts are disclosed.

Bioscope AI firmographics

Firmographics
Name
Bioscope AI
Legal name
Bioscope.ai, Inc.
Website
https://bioscope.ai
Company type
Private
Founded year
2025
Operating status
Operating
Headcount range
51–100 employees
Short description
Bioscope AI is a private US health-tech company that sells a HIPAA-compliant cloud platform combining whole-genome sequencing, microbiome analysis, and EMR data with AI-powered clinical decision support, targeted at concierge physicians and medical practices seeking to deliver precision medicine during patient visits.
Ownership category
akta.pro rank

Bioscope AI industry classification

Industry
Product category
Clinical Decision Support Software
NAICS
Medical and Diagnostic Laboratories (6215), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)
SECONDARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories

Keywords

  • Genomic clinical decision support
  • Whole-genome sequencing
  • Precision medicine platform
  • AI clinical analytics
  • Microbiome analysis services

Where Bioscope AI is headquartered

Location

Headquarters

HQ city
Carmel
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Bioscope AI business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations

Revenue model

  1. SaaS Subscription for Healthcare Practices: Subscription-based access to the Bioscope.ai cloud-based software platform for medical groups and practices. Physicians pay subscription fees to access AI-powered genomic analysis and clinical decision support tools integrated with their patient workflow.
  2. Laboratory Testing Services: Whole genome sequencing and microbiome analysis services ordered by healthcare providers on behalf of patients. The testing includes sample collection kits and processing through contracted testing laboratories.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualSubscription-based SaaS platform access for medical practices

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Bioscope AI product offering

Product offering

Core offering

Bioscope AI sells a cloud-based, HIPAA-compliant clinical decision support SaaS platform that synthesizes whole-genome sequencing (~30x coverage), microbiome analysis, electronic medical records, and lab results into physician-ready clinical insights. Licensed clinicians access an AI chat interface with controlled reasoning chains that flags 22 pharmacogenomic variants and surfaces findings across 15 health dimensions (Metabolic, Cardiovascular, Neurocognitive, Longevity, Immune, Gut, Renal, Hepatic, Cancer, etc.). The company also offers laboratory testing services (whole-genome sequencing and microbiome analysis) and a "Try It On Yourself" self-signup program for individual physician self-analysis.

Product overview

Bioscope.ai is a clinical AI platform built as a unified SaaS offering combining genetic analysis with AI-powered clinical decision support. The core Bioscope.ai Platform serves as the central hub, supported by whole-genome sequencing and microbiome analysis laboratory services. Key modules include an AI Chat Interface for natural language queries, pharmacogenomics (PGx) analysis, and EHR Integration Services. The Try It On Yourself Program enables physicians to personally experience the platform by analyzing their own health data. The platform is accessed via the HIPAA-compliant app.us.bioscope.ai web application.

Differentiator

Problem solved

Functional benefit

Products and services

  • Bioscope.ai Platform HIPAA-compliant, cloud-based clinical decision support platform for physicians and medical practices that reads whole-genome sequencing, microbiome, lab, and full patient history data and synthesizes them into clinical insights before patient visits. Includes the AI Chat Interface, pharmacogenomic analysis, and EMR integration.
  • Whole-Genome Sequencing Laboratory testing service that sequences patient samples at ~30x average coverage, reading approximately 3.2 billion base pairs across 20,000–25,000 genes with all variants reviewed against the latest clinical databases. Ordered by healthcare providers on behalf of patients, with at-home or in-office collection kits.
  • Microbiome Analysis Laboratory testing service that analyzes DNA of microorganisms from stool samples to provide clinical insights into microbial composition and function, ordered by healthcare providers for patients as an optional add-on to whole-genome sequencing.
  • Try It On Yourself Program Self-service offering for individual physicians to use Bioscope AI's clinical AI and genomics capabilities on themselves, including self-enrollment, personal medical data upload, and ordering of whole-genome and microbiome testing kits, intended as a validation path before practice-wide recommendation.

Quantifiable outcome

  • Most physicians are operational within a week of EMR integration
  • +1 more outcomes

Companies that use Bioscope AI

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Bioscope AI technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability7 records

Feature5 records

Bioscope AI partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Contracted Testing LaboratoriescoreOthersBioscope AI contracts with qualified laboratories to perform whole genome sequencing and microbiome analysis on patient samples. A current list of Testing Laboratories is maintained on the Subprocessors page. These laboratories hold appropriate certifications and accreditations for genetic testing services.
  • Auth0coreTechnology or IntegrationAuth0 provides secure authentication and session management for the HIPAA-compliant healthcare platform (app.us.bioscope.ai). Uses encrypted session identifiers with HttpOnly and Secure flags, device identifiers for security monitoring, and automatic session termination after 15 minutes of inactivity.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Bioscope AI competitors and assessment

Company assessment

Broad incumbents

  • Foundation Medicine (Roche): Foundation Medicine provides molecular profiling and genomic analysis to oncologists at scale within the Roche ecosystem; a broad incumbent in clinical genomics whose CDSS-adjacent services compete for the same physician mindshare bioscope.ai targets.
  • GeneDx (formerly Sema4): GeneDx delivers clinical genomic sequencing and interpretation (rare disease, hereditary cancer, PGx) at scale — a broader incumbent whose CDSS-adjacent workflow overlaps with bioscope.ai's clinical genomics offering.
  • Caris Life Sciences: Caris provides molecular profiling (WGS, WTS, proteomics) and AI-driven insights for oncologists, comparable to bioscope.ai's whole-genome + AI clinical decision support model within oncology-focused precision medicine.
  • Verily Life Sciences (Alphabet): Verily is a health-data and precision-medicine platform within Alphabet pursuing AI-driven clinical research and care delivery; broadly comparable to bioscope.ai's data-aggregation approach to clinical AI.

Direct peers

  • SOPHiA Genetics: SOPHiA Genetics operates an AI-driven genomics interpretation platform used by hospitals and clinicians worldwide for clinical decision support, closely paralleling bioscope.ai's evidence-grounded AI for genomic/multi-omic clinical insights.
  • Tempus Labs: Tempus AI combines multi-modal data (genomics, transcriptomics, imaging, clinical records) with AI to deliver clinical decision support and precision medicine insights to physicians — directly comparable to bioscope.ai's WGS + EMR + AI CDSS model across target customer profile.
  • Helix: Helix operates a whole-exome / whole-genome sequencing platform powering clinical and population genomics applications — closely aligned with bioscope.ai's 30x WGS foundation and clinical decision support build.
  • Color Health: Color combines clinical-grade genetic testing with a clinician-facing platform spanning hereditary cancer, pharmacogenomics, and population health — directly comparable to bioscope.ai's WGS + PGx + clinical workflow offering.

Emerging players

  • Owkin: Owkin applies AI to multi-modal clinical and omics data for treatment decision support and drug discovery, overlapping with bioscope.ai's clinician-facing AI analytics on genomic and clinical data.
  • Genomind: Genomind provides PGx and mental-health genetic testing for clinicians — a smaller, niche player in genetic clinical decision support that overlaps with bioscope.ai's PGx module and physician-facing workflow.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Bioscope AI social profiles

Digital presence

Bioscope AI compliance and trust

Trust signal

Compliance6 records

Bioscope AI financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Bioscope AI leadership team

Management profile

Number of profiles

Profiles3 records

Bioscope AI funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Bioscope AI M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bioscope AI

What does Bioscope AI do?

Bioscope AI sells a cloud-based, HIPAA-compliant clinical decision support SaaS platform that synthesizes whole-genome sequencing (~30x coverage), microbiome analysis, electronic medical records, and lab results into physician-ready clinical insights. Licensed clinicians access an AI chat interface with controlled reasoning chains that flags 22 pharmacogenomic variants and surfaces findings across 15 health dimensions (Metabolic, Cardiovascular, Neurocognitive, Longevity, Immune, Gut, Renal, Hepatic, Cancer, etc.). The company also offers laboratory testing services (whole-genome sequencing and microbiome analysis) and a "Try It On Yourself" self-signup program for individual physician self-analysis.

Is Bioscope AI a public or private company?

Bioscope AI is a private company. It is classified as unknown and is currently operating.

When was Bioscope AI founded?

Bioscope AI was founded in 2025. It employs 51 to 100 people.

Where is Bioscope AI based?

Bioscope AI is headquartered in Carmel, United States, in the North America region.

How does Bioscope AI make money?

Two revenue lines are on record. SaaS Subscription for Healthcare Practices are the primary driver. The others are laboratory Testing Services.

Who are Bioscope AI's main competitors?

Broad incumbents on record are Foundation Medicine (Roche), GeneDx (formerly Sema4), Caris Life Sciences and Verily Life Sciences (Alphabet). Direct peers are SOPHiA Genetics, Tempus Labs, Helix and Color Health. Emerging players are Owkin and Genomind.

Does Bioscope AI have an API?

No public API is recorded for Bioscope AI.

What industry is Bioscope AI in?

Bioscope AI's product category is Clinical Decision Support Software. Its primary akta.pro industry code is HLAAALAO, Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays), with a secondary code of HLAGAJAD, Bioinformatics & Multi-omics Analysis Software. Its NAICS code is 6215 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals